Runhui Q. Wu
No.56 Nanlishi Road
Beijing, 100045, China
Beijing, 100045, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Rivaroxaban for pediatric venous thromboembolism in routine clinical practice: Effectiveness and safety from a real-world cohort.
Journal: Thrombosis research
Published: February 13, 2026
Predicting Avatrombopag response in children with immune thrombocytopenia: A multi-view learning framework for tabular missing data.
Journal: Computer methods and programs in biomedicine
Published: February 01, 2026
Overuse of thrombopoietin receptor agonists driven by suboptimal response is associated with myelofibrosis in pediatric immune thrombocytopenia.
Journal: Haematologica
Published: January 31, 2026
Optimizing pediatric ITP therapy: a real-world study on plasma concentration-guided eltrombopag dosing.
Journal: Annals of hematology
Published: October 27, 2025
Machine learning estimation of FVIII pharmacokinetic parameters in Chinese children with severe Hemophilia A.
Journal: NPJ systems biology and applications
Published: September 25, 2025
The Chinese Haemophilia Individualized Prophylaxis (CHIPS): A cost-effective regimen for zero joint bleeding and long-term joint health in boys with Severe Haemophilia A (SHA) on factor replacement.
Journal: Thrombosis research
Published: July 29, 2025
EC2-mutant Mycoplasma pneumoniae in pediatric ITP: severe hemorrhage with accelerated platelet recovery.
Journal: Annals of hematology
Published: July 03, 2025
Urinary metabolomics predicts early rituximab response in steroid-nonresponsive pediatric patients with primary immune thrombocytopenia.
Journal: Annals of hematology
Published: May 07, 2025
Multicenter, real-world observational study of AVA therapy following ELT/HET switching in Chinese children with persistent/chronic primary ITP.
Journal: Annals of hematology
Published: March 09, 2025
A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973.
Journal: Thrombosis research
Published: December 25, 2024
Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 16, 2024
Last Updated: 09/26/2026